Literature DB >> 28069260

Drugs and Medical Devices: Adverse Events and the Impact on Women's Health.

Jennifer L Carey1, Nathalie Nader2, Peter R Chai2, Stephanie Carreiro2, Matthew K Griswold2, Katherine L Boyle3.   

Abstract

A large number of medications and medical devices removed from the market by the US Food and Drug Administration over the past 4 decades specifically posed greater health risks to women. This article reviews the historical background of sex and gender in clinical research policy and describes several approved drugs and devices targeted for use in women that have caused major morbidity and mortality. The intended population for the medications and devices, population affected, approval process, and the basic and legal actions taken against the medication/drug company are also discussed. It is recognized that women are still at risk for harm from unsafe medications and devices, and continued improvements in legislation that promotes inclusion of sex and gender into the design and analysis of research will improve safety for both men and women.
Copyright © 2017 Elsevier HS Journals, Inc. All rights reserved.

Entities:  

Keywords:  medication and device safety; sex and gender

Mesh:

Substances:

Year:  2017        PMID: 28069260      PMCID: PMC5779632          DOI: 10.1016/j.clinthera.2016.12.009

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  71 in total

1.  Lotronex and the FDA: a fatal erosion of integrity.

Authors:  R Horton
Journal:  Lancet       Date:  2001-05-19       Impact factor: 79.321

2.  The schizophrenic career of a "monster drug".

Authors:  William A Silverman
Journal:  Pediatrics       Date:  2002-08       Impact factor: 7.124

3.  Learning about the safety of drugs--a half-century of evolution.

Authors:  Jerry Avorn
Journal:  N Engl J Med       Date:  2011-12-08       Impact factor: 91.245

Review 4.  The development of cervical and vaginal adenosis as a result of diethylstilbestrol exposure in utero.

Authors:  Monica M Laronda; Kenji Unno; Lindsey M Butler; Takeshi Kurita
Journal:  Differentiation       Date:  2012-06-06       Impact factor: 3.880

5.  Revisiting Essure--Toward Safe and Effective Sterilization.

Authors:  Sanket S Dhruva; Joseph S Ross; Aileen M Gariepy
Journal:  N Engl J Med       Date:  2015-09-23       Impact factor: 91.245

6.  Management of perforated essure with migration into small and large bowel mesentery.

Authors:  Lena Braginsky; Sean T George; Stephen R Locher
Journal:  J Minim Invasive Gynecol       Date:  2014-11-11       Impact factor: 4.137

Review 7.  Toxicity of weight loss agents.

Authors:  May Yen; Michele Burns Ewald
Journal:  J Med Toxicol       Date:  2012-06

8.  Signs of genital prolapse in a Swedish population of women 20 to 59 years of age and possible related factors.

Authors:  E C Samuelsson; F T Victor; G Tibblin; K F Svärdsudd
Journal:  Am J Obstet Gynecol       Date:  1999-02       Impact factor: 8.661

9.  The 50th anniversary of the Kefauver-Harris Amendments: efficacy assessment and the randomized clinical trial.

Authors:  J Rick Turner
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-10-03       Impact factor: 3.738

10.  Long-term cancer risk in women given diethylstilbestrol (DES) during pregnancy.

Authors:  L Titus-Ernstoff; E E Hatch; R N Hoover; J Palmer; E R Greenberg; W Ricker; R Kaufman; K Noller; A L Herbst; T Colton; P Hartge
Journal:  Br J Cancer       Date:  2001-01-05       Impact factor: 7.640

View more
  9 in total

1.  Adverse Drug Events and Reactions Managed by Medical Toxicologists: an Analysis of the Toxicology Investigators Consortium (ToxIC) Registry, 2010-2016.

Authors:  Gillian A Beauchamp; Alexandra Amaducci; Marna Rayl Greenberg; Matthew Meyers; Matthew Cook; Robert D Cannon; Kenneth D Katz; Yaron Finkelstein
Journal:  J Med Toxicol       Date:  2019-07-15

2.  Filling the Regulatory Gap: Potential Role of Institutional Review Boards in Promoting Consideration of Sex as a Biological Variable.

Authors:  Korrina A Duffy; Tracy A Ziolek; C Neill Epperson
Journal:  J Womens Health (Larchmt)       Date:  2020-04-08       Impact factor: 2.681

3.  Sex as a Biological Variable: A 5-Year Progress Report and Call to Action.

Authors:  Matthew E Arnegard; Lori A Whitten; Chyren Hunter; Janine Austin Clayton
Journal:  J Womens Health (Larchmt)       Date:  2020-01-22       Impact factor: 2.681

4.  Evidence Map: Reporting of Results by Sex or Gender in Randomized, Controlled Trials with Women Veteran Participants (2008 to 2018).

Authors:  Elisheva R Danan; Kristen Ullman; Ruth S Klap; Elizabeth M Yano; Erin E Krebs
Journal:  Womens Health Issues       Date:  2019-06-25

Review 5.  The spectrum of sex differences in cancer.

Authors:  Joshua B Rubin
Journal:  Trends Cancer       Date:  2022-02-18

Review 6.  Evaluating the evidence for sex differences: a scoping review of human neuroimaging in psychopharmacology research.

Authors:  Korrina A Duffy; C Neill Epperson
Journal:  Neuropsychopharmacology       Date:  2021-11-03       Impact factor: 7.853

Review 7.  Predicting Human Fetal Drug Exposure Through Maternal-Fetal PBPK Modeling and In Vitro or Ex Vivo Studies.

Authors:  Ankit Balhara; Aditya R Kumar; Jashvant D Unadkat
Journal:  J Clin Pharmacol       Date:  2022-09       Impact factor: 2.860

Review 8.  Let's Talk About Sex-Biological Sex Is Underreported in Biomaterial Studies.

Authors:  Bryan D James; Paxton Guerin; Josephine B Allen
Journal:  Adv Healthc Mater       Date:  2020-10-11       Impact factor: 9.933

Review 9.  Considerations and challenges for sex-aware drug repurposing.

Authors:  Jennifer L Fisher; Emma F Jones; Victoria L Flanary; Avery S Williams; Elizabeth J Ramsey; Brittany N Lasseigne
Journal:  Biol Sex Differ       Date:  2022-03-25       Impact factor: 5.027

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.